|
|
 |
|
Viewing report
|
|
|
|
US Osteoporosis Market
Frost & Sullivan, June 2008, Pages: 102
This research service covers the U.S. osteoporosis market from 2004-2014. Included are disease overviews, technology trends, total market revenue forecasts, market segment revenue forecasts, and market share analysis. The market is segmented by product class: bisphosphonates, selective estrogen receptor modulators, calcitonins, parathyroid hormones, and novel therapeutic approaches. Major market challenges, drivers, and restraints and identified and discussed.
This Frost & Sullivan research service titled U.S. Osteoporosis Market provides an overview of osteoporosis and provides market forecasts, along with a complete analysis of key market drivers, restraints, and challenges that are impacting this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following market segments: bisphosphonates, selective estrogen receptor modulators, calcitonins, parathyroid hormones, and novel therapeutic applications, product analysis, and pipeline analysis.
Patient Population Growth and New Screening Guidelines Steer the U.S. Osteoporosis Market Forward
The U.S. osteoporosis market is witnessing consistent growth, with momentum generated by the increase in the diagnosed patient population, technological innovations, introduction of new products, and the rollout of products with decreased dosing. The market registered 24.7 percent growth in 2007 over 2006, owing to the deeper market penetration of existing products and the ever-widening patient population. 'The rapid expansion of the older segment of the population correlates to the age brackets with the highest prevalence for osteoporosis and osteopenia,' notes the analyst of this study. 'This greatly increases the potential patient pool and consequently, the demand for therapeutics.'
Osteoporosis had until recently been considered a woman’s disease, but of late, the incidence among American men is increasing making osteoporosis in men a growing health concern. 'Although guidelines for the screening of women for osteoporosis have been in place for years, guidelines for men were only established in 2008,' notes the analyst. 'The American College of Physicians published guidelines in May 2008, recommending doctors to start screening men aged 65 and above for osteoporosis.' In February 2008, the National Osteoporosis Foundation drew up guidelines for screening men for osteoporosis, but the U.S. Preventative Services Task Force has not set up the guidelines. The new guidelines for the screening of men could serve to increase the population of diagnosed patients and improve market prospects.
New Products with Novel Therapeutic Approaches Enhance Market Prospects
Low awareness of the risks associated with osteoporosis and the need for screening remain major roadblocks for the market. In addition, the side effects associated with medications to treat osteoporosis could discourage patients from using these therapies on a long-term basis. For example bisphosphonates, which are commonly used for the treatment of osteoporosis, have numerous side effects, including nausea, abdominal cramping, and esophageal ulceration. Moreover, the use of bisphosphonates has been linked to the development of osteonecrosis of the jaw, commonly referred to as dead jaw. While Evista may increase the risk of developing blood clots, and in post-menopausal women, who are considered high risk for heart attack, there may be an increased chance of dying from stroke. The need for the development of more effective medications with a good safety profile has never been more apparent. Medications that meet the safety criteria and have negligible side effects are more commonly recommended by physicians. Drug delivery is another aspect that is crucial in the choice of medication. Most medicines are administered orally, while others are administered intranasally or through injections. Medications with decreased dosing are often the preferred options.
In such a scenario, the introduction of new products that address crucial unmet needs will enhance market prospects. For example, denosumab is the first therapeutic monoclonal antibody expected to be launched in the U.S. for Osteoporosis. Clinical trials have indicated that denosumab inhibits all stages of osteoclast activity and helps arrest bone loss. Odanacatib is an oral cathepsin K inhibitor that enables the prevention of bone resorption. New products, such as these, could invigorate the market by offering breakthrough approaches to treatment in a market inhibited by impending patent expiries.
Customers who bought this item also bought
Chinese Markets for Osteoporosis Drugs
Osteoporosis Market Forecast
Womens Health Postmenopausal Osteoporosis
Musculo-Skeletal-Disorders Osteoporosis
Osteoporosis Therapeutics - A Global Market Perspective
Osteoporosis Therapeutics - Global Strategic Business Report
Thought Leader Insight & Analysis: Osteoporosis
Postmenopausal Osteoporosis Therapy Area Pipeline Report
Osteoporosis - Novel Agents to Battle for Payer Acceptance
Pipeline Insight: Osteoporosis - Intermittent Dosing Drives Market Growth
Osteoporosis - The Science Of Compliance
U.S. Osteoporosis Therapeutics Markets
|
|
|
|
